Accelerate Diagnostics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Accelerate Diagnostics, Inc., an in vitro diagnostics firm, has historically provided advanced solutions for managing severe infections across the United States, Europe, and the Middle East. The company's primary offering, the Accelerate Pheno system, is an in vitro diagnostic platform engineered for the swift identification and antibiotic susceptibility analysis of pathogens, including both gram-positive and gram-negative organisms, linked to serious or healthcare-associated infections. Complementing this, the Accelerate PhenoTest BC Kit delivers identification and antibiotic susceptibility results for patients suspected of life-threatening bacteremia or fungemia. In recent developments, the company secured 510(k) clearance from the U.S. Food and Drug Administration for its Accelerate Arc system in September 2024, designed to automate positive blood culture sample preparation. Furthermore, its next-generation Accelerate WAVE system, targeting even faster antimicrobial susceptibility testing in approximately 4.5 hours, completed preclinical trials in August 2024 and was submitted for FDA 510(k) clearance in March 2025. Accelerate Diagnostics operated with a hybrid revenue model, selling instruments and generating recurring income from consumable test kits and service contracts. However, the company initiated Chapter 11 bankruptcy proceedings in May 2025 and subsequently completed the sale of certain assets in August 2025, moving toward a liquidation plan. Its shares are now quoted on the OTC Pink marketplace under the symbol AXDXQ, with all outstanding equity interests slated for cancellation. The entity was incorporated in 1982 and maintains its headquarters in Tucson, Arizona.
Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets
Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results
Accelerate Diagnostics, Inc. (AXDX) Q3 2024 Earnings Call Transcript
Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates
Accelerate Diagnostics Reports Third Quarter 2024 Financial Results
Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results
Accelerate Diagnostics Stock Down Despite FDA Clearance for Arc System
Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System
Accelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial
Accelerate Diagnostics, Inc. (AXDX) Q2 2024 Earnings Call Transcript
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
Accelerate Diagnostics Reports Second Quarter 2024 Financial Results
Accelerate Diagnostics Announces a Successful Completion of its WAVE™ Pre-Clinical Trial
Accelerate Diagnostics Scheduled Call to Review 2024 Second Quarter Results
Dead Cat Bounce: 3 Stocks to Sell Before They Plunge Again
Accelerate Diagnostics, Inc. (AXDX) Q1 2024 Earnings Call Transcript
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates
Accelerate Diagnostics Reports Preliminary First Quarter 2024 Financial Results